The cure for cancer: SYBB Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : The cure for cancer: SYBB

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: richard wilson who wrote ()	8/16/1999 8:52:00 AM
From: Maurice Winn	of 2

Oncolytics private placement details from 4 August: siliconinvestor.com Oncolytics Biotech Inc. has 9.75m shares [when warrants fully exercized] of which 6m are owned by Synsorb [SYBB]. Oncolytics owns the rights to the activated Ras pathway reovirus. IPO to come 'shortly'. The 1.5m shares [convertible warrants] sold raised $900,000 with another 1.5m x $0.75 = $1.125m to come when these warrants are exercized within two years from an IPO for total of $2m. Synsorb market capitalisation is $61.68m at $2.0625 Daily share price and volumes: siliconinvestor.com Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext